- Conditions
- Phase IB, Avutometinib, RAS Pathway, Endometrial
- Interventions
- Avutometinib, defactinib, Everolimus
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 22,494
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
- Interventions
- A166
- Drug
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Seizures
- Interventions
- Retigabine, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
- Conditions
- Melanoma, Skin Neoplasms
- Interventions
- Imatinib mesylate (STI571)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Cirrhosis, Hepatic Cirrhosis
- Interventions
- IDN-6556, Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Jolla, California • Loma Linda, California + 21 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- NCX 470 0.1%, Latanoprost 0.005%
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 63
- States / cities
- Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Glioblastoma
- Interventions
- Abemaciclib, Surgery
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Peanut Allergy
- Interventions
- VLP Peanut, Placebo
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more
- Conditions
- Dermatitis, Atopic
- Interventions
- tacrolimus ointment, pimecrolimus cream
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- placebo, linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 38
- States / cities
- Sheffield, Alabama • Chula Vista, California • Costa Mesa, California + 32 more
- Conditions
- Vaginal Vault Prolapse, Post-Hysterectomy Vaginal Vault Prolapse, Prolapse, Vaginal
- Interventions
- Intraperitoneal Uterosacral Ligament Suspension, Extraperitoneal Uterosacral Ligament Suspension
- Procedure
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Sensipar (Cinacalcet HCl)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- Nectero EAST System
- Drug
- Lead sponsor
- Nectero Medical, Inc.
- Industry
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 32 more
- Conditions
- Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
- Interventions
- 5 mg Serlopitant Tablets
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
- Conditions
- Septic Shock
- Interventions
- Plasma, Balanced crystalloids
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo matching BI 690517, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 53
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- AR11, Placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 7
- States / cities
- Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
- Conditions
- Painful Lumbosacral Radiculopathy
- Interventions
- VX-548, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Bakersfield, California • Banning, California + 48 more
- Conditions
- Lung Cancer
- Interventions
- radiation therapy
- Radiation
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Other
- Eligibility
- Up to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
- Interventions
- PF- 00610355, Placebo, Salmeterol
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 30
- States / cities
- Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more
- Conditions
- Breast Cancer
- Interventions
- Cetuximab, Ixabepilone
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
- Interventions
- Olutasidenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Miami, Florida • Houston, Texas
- Conditions
- Chronic Kidney Disease, Hypertension
- Interventions
- Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- SARS-CoV 2, Viral Infection, COVID 19
- Interventions
- Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
- Biological · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas